Skip to main content

Month: March 2021

IDEX Biometrics – CFO

Oslo, Norway – 31 March 2021 – IDEX Biometrics ASA, today announced that Derek P. D’Antilio will step down from his position as Chief Financial Officer effective 23 April 2021. Mr. D’Antillio has accepted a position with another company. IDEX has initiated the process of finding his successor and expects to appoint the Company’s next CFO by 1 May 2021. The company has appointed Erling Svela, VP of Finance of IDEX as interim CFO effective 24 April 24 2021. Mr. D’Antilio will remain with IDEX in an advisory role to assist with an orderly transition. “On behalf of IDEX, I want to thank Derek for his many and significant contributions to IDEX,” said Chief Executive Officer, Vince Graziani. “Derek is a well-respected senior executive who, as Chief Financial Officer beginning in 2019, has been instrumental in raising capital, leading...

Continue reading

Craig Macfarlane to become the CFO of LHV UK Limited

As of 21 June 2021, Craig Macfarlane will become the Chief Financial Officer of LHV UK Limited, a subsidiary of AS LHV Group. The CFO will also be appointed to the Board of Directors of LHV UK Limited. As a professional with an extensive experience in financial management Craig Macfarlane will lead the financial management of LHV UK Limited during the process of applying for a banking licence and after obtaining the banking licence, subject to regulatory approval. Since March 2019, Macfarlane has worked as Deputy CFO in Tandem Bank and before that served as Finance Director in Amicus Group PLC from February 2016 until March 2019. Previously he has also contributed in Leeds Building Society’s, Aldemore bank, Lloyds Banking Group and National Australia Group. He has no occupations in managements of any companies. Craig Macfarlane and the...

Continue reading

LHV UK Limitedi finantsjuhiks saab Craig Macfarlane

AS-i LHV Group tütarettevõtte LHV UK Limited finantsjuhiks saab alates 21. juunist 2021 Craig Macfarlane. Ühtlasi määratakse ta ettevõtte juhtimisorgani (board of directors) liikmeks. Craig Macfarlane on laialdase finantsjuhtimise kogemusega professionaal, kelle ülesandeks saab LHV UK Limited’i finantside juhtimine pangalitsentsi taotlemisel ja pangalitsentsi saamise järgselt, eeldusel, et ettevõte saab regulaatori kooskõlastuse. Macfarlane on alates 2019. aasta märtsist töötanud finantsjuhi asetäitjana Tandem pangas ning veebruarist 2016 kuni märtsini 2019 töötas finantsjuhina Amicus Group PLC’s. Eelnevalt on ta töötanud ka Leeds Building Society’s, Aldemore pangas, Lloyds Banking Groupis ja National Australia Groupis. Ta ei kuulu ühegi äriühingu juhtorganisse. Craig Macfarlane ega temaga seotud isikud ei oma AS-i LHV Group aktsiaid. LHV...

Continue reading

Suomalaisten vaurastuminen hataralla pohjalla, Ruotsissa uskalletaan sijoittaa

Aktia Pankki OyjLehdistötiedote30.3. 2021 klo 8.00 Ruotsalaiset ovat suomalaisia aktiivisempia ja monipuolisempia säästäjiä ja sijoittajia, kertoo Aktian teettämä kyselytutkimus. Vain harvalla suomalaisella on vaurastumissuunnitelma ja vielä harvemmalla välineitä vaurastumiseen, kuten sijoituksia tai muuta omaisuutta. Aktian teettämän kyselytutkimuksen mukaan suomalaiset ovat säästäjinä vielä kaukana länsinaapurin tasosta: suomalaisten keskimääräiset säästöt ja sijoitukset ovat kautta linjan ruotsalaisia pienemmät, ja kyselyyn vastanneista suomalaisista 46 ja ruotsalaisista jopa 62 prosentilla on osake- tai rahasto-omistuksia. Puolella suomalaisista säästöt ovat edelleen pankkitilillä, ja noin kolmanneksella kyselyyn vastanneista suomalaisista ei ole lainkaan säästöjä tai sijoituksia. Myönteistä kehitystä on kuitenkin näkyvissä: Aktian...

Continue reading

Finländarnas ekonomiska välstånd står på en svag grund, i Sverige vågar man placera

Aktia Bank AbpPressmeddelande31.03.2021 kl. 8.00 Svenskarna sparar och placerar aktivare och mångsidigare än finländarna framkommer det av undersökningen som Aktia låtit göra. Få finländare har en förmögenhetsplan och ännu färre har verktyg för att bli förmögnare, så som investeringar eller övrig egendom. Enligt undersökningen som Aktia låtit göra ligger finländarna som placerare ännu långt under nivån i vårt västra grannland: finländarnas genomsnittsbesparingar och -placeringar är konsekvent mindre än svenskarnas. Bland enkätdeltagarna svarar 46 procent av finländarna och 62 procent av svenskarna att de äger aktier eller fondandelar. Häften av finländarnas besparingar ligger fortfarande på bankkonton och en tredjedel av de finländare som svarat på enkäten har inga besparingar eller placeringar alls. Det går ändå att skönja en positiv...

Continue reading

Finns have limited skills to accumulate wealth, while Swedes have courage to invest

Aktia Bank PlcPress release31.3. 2021 at 8.00 a.m. Swedes save and invest their money more actively and diversely than Finns, according to a consumer survey commissioned by Aktia. Few Finns have prosperity plans and even fewer have the investments or other assets necessary to accumulate wealth. A survey commissioned by Aktia indicates that Finnish people are far behind the Swedes as savers. The average savings and investments of Finns are, by all measures, smaller than those of Swedish people; 46 per cent of Finns responding to the survey and 62 per cent of Swedes had stock or fund holdings. Half of Finns still keep their savings on their bank account, and approximately a third of Finnish respondents did not have any savings or investments whatsoever. Positive developments are on the horizon, however. Compared to Aktia’s 2019 survey,...

Continue reading

Roche launches Elecsys Epstein-Barr Virus (EBV) immunoassay panel to improve EBV infection staging

The Elecsys EBV panel accurately identifies the EBV infection stage from a single blood sample, which means less confirmatory testing and, potentially, faster diagnosis for patients Clear and quick diagnosis of acute infection allows physicians to decide faster on treatment for transplant patients The EBV panel can be used to rule out other acute infections, such as missed HIV infectionsBasel, 31 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Elecsys® EBV panel has launched in countries accepting the CE Mark. Roche will file for approval with the FDA in the future. The Elecsys® EBV panel consists of three immunoassays: Elecsys EBV IgM, Elecsys EBV VCA IgG, and Elecsys EBV EBNA IgG, that detect antibodies specific to the Epstein-Barr virus (EBV), at different stages of infection. When used in combination,...

Continue reading

Byggmästare Anders J Ahlström Holding AB (publ): Årsredovisning 2020

Byggmästare Anders J Ahlström Holding AB (publ) publicerar idag årsredovisning för 2020 för moderbolaget respektive för koncernen. Bolagets årsredovisning för 2020 finns nu tillgänglig på Bolagets webbplats, https://andersjahlstrom.se/. Kalendarium 2021Årsstämma: 18 majDelårsrapport januari–mars: 18 majDelårsrapport januari–juni: 27 augustiDelårsrapport januari–september: 19 novemberBokslutskommuniké: 25 februari 2022 För ytterligare information, vänligen kontakta Byggmästare Anders J Ahlström Holding AB:s VD Tomas Bergström på +46 70 317 80 92. Denna information lämnades för offentliggörande av bolagets verkställande direktör den 31 mars 2021 kl 07:00. Byggmästarens B-aktier handlas sedan 2014 på Nasdaq First North GM Sweden (ISIN SE0006510491).Avanza Bank AB är Byggmästarens Certified Adviser. Kontaktuppgifter till Avanza Bank AB Email:...

Continue reading

VirTra Announces Pricing of $18.0 Million Registered Direct Offering

TEMPE, Ariz., March 31, 2021 (GLOBE NEWSWIRE) — VirTra, Inc. (NASDAQ: VTSI), a global provider of training simulators for the law enforcement, military, educational, and commercial markets, today announced that it has entered into a securities purchase agreement with certain institutional investors, to purchase 3 million shares of common stock at a price of $6.00 per share, which is a premium to market based on the Nasdaq “Minimum Price” rule. The total gross proceeds of the offering are $18 million, before deducting the placement agents’ fees and other estimated offering expenses. Roth Capital Partners acted as the lead placement agent in this offering. Lake Street Capital Markets acted as co-placement agent for the offering. Maxim Group LLC acted as a financial advisor to the Company in connection with the offering. The registered...

Continue reading

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

MONT-SAINT-GUIBERT, Belgium, March 31, 2021 (GLOBE NEWSWIRE) — Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced on March 29, 2021 a capital increase of 200,000 new shares of the Company to Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor. As a result, the Company’s share capital is increased to 50,123,200.33 EUR and is represented by 14,405,156 shares. This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions. Figures – Modified on 29 March 2021 following the Capital...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.